Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

Part of paid clinical trials in Portland, Oregon.

Sponsor
OHSU Knight Cancer Institute
Study ID
NCT06784167
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Non-Interventional Study — OTHER
    Non-interventional study

Study Details

This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as measles, mumps and rubella, among others in patients with multiple myeloma and non-Hodgkin lymphoma.

Key Dates

First listed
Jan 20, 2025
Start date
Mar 10, 2025
Status verified
Sep 2025
Primary completion
Jan 11, 2027
Completion
Apr 12, 2027

Study Design

Enrollment
45 participants (estimated)

Arms

  • Arm: Observational
    Patients may receive up to 3 doses of pneumococcal and/or tetanus vaccine per institutional policy of revaccination. Patients undergo blood sample collection and have medical records reviewed throughout the study.

Primary Outcome Measure

Preserved immunity [ Time Frame: Up to 12 months after CAR-T cell infusion ]

Locations (1)

FacilityCityStateZIPSite coordinators
OHSU Knight Cancer InstitutePortlandOregon97239
Amrita Desai
[email protected]
503-494-8534
Amrita Desai (PRINCIPAL_INVESTIGATOR)

Find similar trials in Portland, OR

By condition
Leukemia (other)Multiple myeloma
By specialty
OncologyBlood cancer
By research site
OHSU Knight Cancer Institute· Portland, OR

Related Studies